Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD
July 15th 2024Switching from aflibercept (Eylea; Regeneron Pharmaceuticals) to biosimilar ranibizumab (Lucentis; Genentech) for neovascular age-related macular degeneration could be more cost effective for patients.
Read More
Results From the FLOW Trial Show Benefits of Semaglutide on Chronic Kidney Disease
June 24th 2024Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.
Read More